Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression
Status:
Completed
Trial end date:
2020-03-23
Target enrollment:
Participant gender:
Summary
This study evaluated the efficacy and safety of the compound MIJ821 compared to placebo in
patients aged from 18 to 65 years diagnosed with treatment-resistant depression. The study
was conducted in the US and in Europe (Spain). The MIJ821 was administered via infusion on a
weekly or bi-weekly basis. The efficacy was measured after 24 hours using a specific golden
standard scale, the Montgomery-Asberg Depression Rating Scale. The study duration was 6 weeks
of treatment plus 1 month of follow up period.